Aktienanalyse zu Xenon Pharmaceuticals Inc (XENE)XENEXenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc. is a Canada-based neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing therapeutics to improve the lives of people living with neurological and psychiatric disorders. The Company is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the advanced, clinically validated potassium channel modulator in late-stage clinical development for the treatment of multiple indications that include epilepsy, including focal onset seizures (FOS), and primary generalized tonic-clonic seizures (PGTCS), as well as neuropsychiatric disorders including major depressive disorder (MDD), and bipolar depression (BPD). The Company is evaluating multiple therapeutic candidates targeting Kv7, Nav1.7, and Nav1.1 across various indications. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Xenon Pharmaceuticals is currently priced at $59.99, with a recent RSI of 38.054 indicating it is oversold. However, the company reported a significant net income loss of -$110.736 million in Q2 2026, which raises concerns about its financial health. While the stock has seen a year-to-date increase of +34.84%, the recent insider selling activity has surged by 904.19%, which could signal a lack of confidence among insiders. Given these factors, it may be prudent to hold off on buying until there are clearer signs of recovery and stability.

3 analysts cover XENE: 3 rate it Buy, 0 Hold and 0 Sell. The average price target is 54.09.